pharmaphorum

AUGUST 10, 2020

Swiss medical data specialist Sophia Genetics has launched a platform that will sift through data generated at more than 1,000 hospitals around the world to try to work out how the COVID-19 pandemic will evolve in the coming months and years. Combined, they use machine learning to discover abnormalities predictive of disease evolution.

Genetics 136

Genetics Genomics Genome Vaccine 136

The Pharma Data

MARCH 24, 2021

76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. 100% efficacy against severe or critical disease and hospitalisation.

Vaccine 52

Vaccine Vaccination Radiology Trials 52

The Pharma Data

MARCH 22, 2021

79% vaccine efficacy at preventing symptomatic COVID-19. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo.

Trials 52

Trials Vaccination Vaccine Radiology 52

Delveinsight

DECEMBER 10, 2020

AstraZeneca’s COVID-19 vaccine data suggest single-dose efficacy. The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

The Pharma Data

APRIL 20, 2022

These tests look for signs of genetic abnormalities in a fetus by testing a sample of blood from the pregnant person. director of the FDA’s Center for Devices and Radiological Health. director of the FDA’s Center for Devices and Radiological Health. These genetic abnormalities can cause serious health conditions.

Genetics 52

Genetics Cosmetics Radiology Production 52

The Pharma Data

NOVEMBER 18, 2020

. “Today’s authorization for a complete at-home test is a significant step toward FDA’s nationwide response to COVID-19,” Jeff Shuren, director of FDA’s Center for Devices and Radiological Health, said in a statement. Like PCR, the new test repeatedly copies genetic material until it reaches detectable levels.

FDA Approval 52

FDA Approval Vaccine Vaccination Genetics 52

The Pharma Data

NOVEMBER 20, 2020

Though talk of two highly effective vaccines came this week, they will not be widely available until spring of 2021. Lab tests that look for the coronavirus’s genetic material using a technique called polymerase chain reaction (PCR) are still considered the gold standard for detecting the virus.

Vaccination 52

Vaccination Vaccine Genetics Radiology 52